Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Here's Why Mylan Fell 26.6% in 2019

TheMotleyFool

0 0

Shares of Mylan (NASDAQ: MYL) fell over 26% last year, according to data provided by S&P Global Market Intelligence. The generic drug manufacturer struggled to overcome its negative association in the national discussion related to drug pricing practices and became embroiled in an industrywide price-fixing lawsuit brought by 44 state attorneys general.

The performance of the pharma stock looks even worse when considering that the S&P 500 delivered a 28.8% gain in 2019. Can plans to combine with Upjohn, the generic drug division of Pfizer (NYSE: PFE), provide relief to shareholders in 2020?

Image source: Getty Images.

Source Fool.com

Like: 0

PFE

Share